Thesis

58 Part I Chapter 2 References 1. Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med. 1996; 37: 975-978. 2. Horger M, Eschmann SM, Pfannenberg C, Vonthein R, Besenfelder H, Claussen CD, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004; 183: 655-661. 3. Bombardieri E, Aktolun C, Baum RP, BishofDelaloye A, Buscombe J, Chatal JF, et al. Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003; 30: BP99-106. 4. Donohoe K, Brown M, Collier B, Carretta R, Henkin R, O’Mara R, et al. Procedure Guideline for Bone Scintigraphy v3.0. 2003. In: Society of Nuclear Medicine and Molecular Imaging Procedure Standards. 2003. http://snmmi.files.cms-plus.com/docs/pg_ ch34_0403.pdf. Accessed 15/11/2015. 5. Commissie Kwaliteitsbevordering Nederlandse Vereniging Nucleaire Geneeskunde. Skeletscintigrafie. In Barneveld P, van Urk P, editors. Aanbevelingen Nucleaire Geneeskunde. Neer: Kloosterhof acquisitie services – uitgeverij; 2007. pp. 155-160. 6. Société française de médecine nucléaire et imagerie moléculaire (SFMN). Guidelines for writing protocols for bone scintigraphy. Médecine Nucléaire. 2012; 687-697. 7. Beheshti M, Mottaghy FM, Paycha F, Behrendt FF, Van den Wyngaert T, Fogelman I, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015; 42: 1767-77. 8. Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010; 51: 1813-20. 9. Stauss J, Hahn K, Mann M, De Palma D. Guidelines for paediatric bone scanning with 99mTc-labelled radiopharmaceuticals and 18F-fluoride. Eur J Nucl Med Mol Imaging. 2010; 37: 1621-8. 10. Fogelman I, Gnanasegaran G, Van der Wall H. Radionuclide and Hybrid Bone Imaging. Berlin and Heidelberg: Springer-Verlag; 2013. 11. Yang DC, Ratani RS, Mittal PK, Chua RS, Pate SM. Radionuclide three-phase whole-body bone imaging. Clin Nucl Med. 2002; 27: 419426. 12. Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med. 1998; 42: 43-48. 13. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med. 1999; 29: 69-79. 14. Cook GJ, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001; 31: 206-211. 15. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun. 2002; 23: 857-864. 16. GallowitschHJ, Kresnik E, Gasser J, KumnigG, Igerc I, Mikosch P, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence andmetastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38: 250-256. 17. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005; 46: 1356-1367. 18. Orzel JA, Sawaf NW, RichardsonML. Lymphoma of the skeleton: scintigraphic evaluation. AJR Am J Roentgenol. 1988; 150: 1095-1099. 19. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med. 2000; 27: 1305-1311. 20. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16: 3375-3379.

RkJQdWJsaXNoZXIy MjY0ODMw